HCW Biologics Inc. announced the results of its 2024 Annual Meeting of Stockholders, which was held on Thursday, June 14. The shareholders voted to elect a Class III director and ratified the company's choice of an independent registered public accounting firm for the current fiscal year.
In the meeting, the company's stockholders approved the election of Hing C. Wong as a Class III director. Wong, who will serve a three-year term expiring at the 2027 Annual Meeting of Stockholders, received 24,165,521 votes for his election, with 1,348,261 withheld and 2,313,942 broker non-votes. His election was based on the recommendation of HCW Biologics' Board of Directors as detailed in the company's 2024 Proxy Statement.
Additionally, stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for HCW Biologics for the fiscal year ending December 31, 2024. The accounting firm's appointment was confirmed with 27,788,079 votes in favor, 7,646 against, and 31,999 abstentions.
HCW Biologics, based in Miramar, Florida, operates within the pharmaceutical preparations industry under the organization name 03 Life Sciences. It is incorporated in Delaware and is listed on The Nasdaq Stock Market LLC under the ticker symbol NASDAQ:HCWB. The company has designated itself as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.